Luisa Pascucci

Prof. Luisa Pascucci

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Journal of Controlled Release
Verified
Journal Article
Closed access
LPLuisa Pascucci
Luisa Pascucci
VCValentina Coccè
Valentina Coccè
ABArianna Bonomi
Arianna Bonomi
DADiletta Ami
Diletta Ami
PCPiero Ceccarelli
Piero Ceccarelli
Augusto PessinaAugusto Pessina
Augusto Pessina

31 January 2017 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
CSClaudia Lo Sicco
Claudia Lo Sicco
DRDaniele Reverberi
Daniele Reverberi
Carolina BalbiCarolina Balbi
Carolina Balbi
VUValentina Ulivi
Valentina Ulivi
EPElisa Principi
Elisa Principi
Roberta TassoRoberta Tasso
Roberta Tasso
Mesenchymal Stem Cells (MSCs) are effective therapeutic agents enhancing the repair of injured tissues mostly through their paracrine activity. Increasing evidences show that besides the secretion of soluble molecules, the release of extracellular vesicles (EVs) represents an alternative mechanism adopted by MSCs. Since macrophages are essential contributors toward the resolution of inflammation, which has emerged as a finely orchestrated process, the aim of the present study was to carry out a detailed characterization of EVs released by human adipose derived-MSCs to investigate their involvement as modulators of MSC anti-inflammatory effects inducing macrophage polarization. The EV-isolation method was based on repeated ultracentrifugations of the medium conditioned by MSC exposed to normoxic or hypoxic conditions (EVNormo and EVHypo). Both types of EVs were efficiently internalized by responding bone marrow-derived macrophages, eliciting their switch from a M1 to a M2 phenotype. In vivo, following cardiotoxin-induced skeletal muscle damage, EVNormo and EVHypo interacted with macrophages recruited during the initial inflammatory response. In injured and EV-treated muscles, a downregulation of IL6 and the early marker of innate and classical activation Nos2 were concurrent to a significant upregulation of Arg1 and Ym1, late markers of alternative activation, as well as an increased percentage of infiltrating CD206pos cells. These effects, accompanied by an accelerated expression of the myogenic markers Pax7, MyoD, and eMyhc, were even greater following EVHypo administration. Collectively, these data indicate that MSC-EVs possess effective anti-inflammatory properties, making them potential therapeutic agents more handy and safe than MSCs. © Stem Cells Translational Medicine 2017

1 December 2015 in Cell Transplantation
Verified
Journal Article
Open access
ANDREA DEL FATTOREANDREA DEL FATTORE
ANDREA DEL FATTORE
RLRosa Luciano
Rosa Luciano
LPLuisa Pascucci
Luisa Pascucci
BGBianca Maria Goffredo
Bianca Maria Goffredo
EGEzio Giorda
Ezio Giorda
MMMaurizio Muraca
Maurizio Muraca
The immunomodulatory activity of mesenchymal stem cells (MSCs) is largely mediated by paracrine factors. We have recently shown that the immunosuppressive effects of MSCs on B lymphocytes in peripheral blood mononuclear cell (PBMC) culture can be reproduced by extracellular vesicles (EVs) isolated from MSC culture supernatants. Here we investigated the effect of bone marrow-derived MSC-EVs on T cells on PBMC cultures stimulated with anti-CD3/CD28 beads. Stimulation increased the number of proliferating CD3+ cells as well as of regulatory T cells (Tregs). Coculture with MSCs inhibited the proliferation of CD3+ cells, with no significant changes in apoptosis. Addition of MSC-EVs to PBMCs did not affect proliferation of CD3+ cells, but induced the apoptosis of CD3+ cells and of the CD4+ subpopulation and increased the proliferation and the apoptosis of Tregs. Moreover, MSC-EV treatment increased the Treg/Teff ratio and the immunosuppressive cytokine IL-10 concentration in culture medium. The activity of indoleamine 2,3-dioxygenase (IDO), an established mediator of MSC immunosuppressive effects, was increased in supernatants of PBMCs cocultured with MSCs, but was not affected by the presence of MSC-EVs. MSC-EVs demonstrate immunomodulatory effects on T cells in vitro. However, these effects and the underlying mechanisms appear to be different from those exhibited by their cells of origin.

21 November 2014 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
ANDREA DEL FATTOREANDREA DEL FATTORE
ANDREA DEL FATTORE
RLRosa Luciano
Rosa Luciano
RSRossana Saracino
Rossana Saracino
GBGiulia Battafarano
Giulia Battafarano
CRCristiano Rizzo
Cristiano Rizzo
MMMaurizio Muraca
Maurizio Muraca
Malignant glial tumors, including glioblastoma multiforme, account for 15 - 20% of pediatric CNS malignancies. They are most resistant to therapy and are associated with a poor prognosis. Given the ability of mesenchymal stem cells (MSCs) to affect glioma growth, we investigated the effects of extracellular vesicles (EVs) derived from MSCs on U87MG glioblastoma cells line. EVs were isolated from culture media of MSCs from different sources, including bone marrow (BM), umbilical cord (UC) and adipose tissue (AT) and added to U87MG culture. The internalization and the effects of BM-, UC- and AT-MSC-EVs on proliferation and apoptosis of tumor cells were evaluated. Both confocal microscopy and FACS analysis showed internalization of EVs into tumor cells. BM- and UC-MSC-EVs decreased cell proliferation, while an opposite effect was observed with AT-MSC-EVs. Moreover, both BM- and UC-MSC-EVs induced apoptosis of glioblastoma cells, while AT-MSC-EVs had no effect. Loading UC-MSC-EVs with Vincristine further increased cytotoxicity when compared both to the free drug and to untreated EVs. Different effects of MSC-EVs on cancer cells were observed depending on their tissue of origin. Moreover, MSC-EVs can deliver antiblastic drugs to glioblastoma cells.

1 September 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
BCBarbara Crivelli
Barbara Crivelli
TCTheodora Chlapanidas
Theodora Chlapanidas
SPSara Perteghella
Sara Perteghella
ELEnrico Lucarelli
Enrico Lucarelli
LPLuisa Pascucci
Luisa Pascucci
Maria Luisa TorreMaria Luisa Torre
Maria Luisa Torre

8 March 2017 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
Carolina BalbiCarolina Balbi
Carolina Balbi
Martina PiccoliMartina Piccoli
Martina Piccoli
Lucio BarileLucio Barile
Lucio Barile
Andrea PapaitAndrea Papait
Andrea Papait
Andrea ArmirottiAndrea Armirotti
Andrea Armirotti
Sveva BolliniSveva Bollini
Sveva Bollini
Human amniotic fluid stem cells (hAFS) have shown a distinct secretory profile and significant regenerative potential in several preclinical models of disease. Nevertheless, little is known about the detailed characterization of their secretome. Herein we show for the first time that hAFS actively release extracellular vesicles (EV) endowed with significant paracrine potential and regenerative effect. c-KIT+ hAFS were isolated from leftover samples of amniotic fluid from prenatal screening and stimulated to enhance EV release (24 hours 20% O2 versus 1% O2 preconditioning). The capacity of the c-KIT+ hAFS-derived EV (hAFS-EV) to induce proliferation, survival, immunomodulation, and angiogenesis were investigated in vitro and in vivo. The hAFS-EV regenerative potential was also assessed in a model of skeletal muscle atrophy (HSA-Cre, SmnF7/F7 mice), in which mouse AFS transplantation was previously shown to enhance muscle strength and survival. hAFS secreted EV ranged from 50 up to 1,000 nm in size. In vitro analysis defined their role as biological mediators of regenerative, paracrine effects while their modulatory role in decreasing skeletal muscle inflammation in vivo was shown for the first time. Hypoxic preconditioning significantly induced the enrichment of exosomes endowed with regenerative microRNAs within the hAFS-EV. In conclusion, this is the first study showing that c-KIT+ hAFS dynamically release EV endowed with remarkable paracrine potential, thus representing an appealing tool for future regenerative therapy. Stem Cells Translational Medicine 2017;6:1340–1355